drugset / Trial / NCT03680560
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.
Timeline
- Start
- 2019-03-13
- Primary completion
- 2020-03-12
- Completion
- 2020-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACTR T Cell Product | Cell therapy | — | — |
| Background | Trastuzumab | Monoclonal antibody | — | — |